Open Label Extension Study of Conatumumab and Ganitumab (AMG 479)
Status:
Completed
Trial end date:
2020-02-05
Target enrollment:
Participant gender:
Summary
The purpose of this protocol is to allow continued treatment with conatumumab and/or
ganitumab, with or without chemotherapy, to participants who completed a separate
Amgen-sponsored conatumumab or ganitumab study without disease progression whose previous
studies were closed.